news Archives - Page 71 of 100 - Journal for Clinical Studies

Current Edition

news

Bayer/Nektar experimental inhaled antibiotic fails in Phase III

Bayer and Nektar Therapeutics’ experimental inhaled antibiotic has failed to hit key targets assessing its effect on survival in patients with Gram-negative pneumonia...

29 November 2017 news antibiotic | Bayer

Continue Reading →

news

Owlstone Medical’s Breath Biopsy Platform integrated into GSK’s Phase II Respiratory Disease Clinical Trial

Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, today announced that GSK, a world leader in respiratory, will incorporate Owlstone ...

29 November 2017 news biopsy | breathalyzer

Continue Reading →

news

Bevacizumab leads clinical trial activity for monoclonal antibodies, says GlobalData

When tracking clinical trial activity across the world, GlobalData, a leading data and analytics company, identified 5,273 industry monoclonal antibodies (mAb) clinic...

29 November 2017 news clinical trial | drugs

Continue Reading →

news

Cristal Therapeutics Awarded €2.5 Million Horizon 2020 Grant to Advance Its CriPec®-docetaxel Through Phase 2 Trials

Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet pat...

29 November 2017 news cancer | grant

Continue Reading →

news

SOTIO Broadens Its Phase II Clinical Trial Program in Ovarian Cancer

SOTIO, a biotechnology company owned by the PPF Group, today announced the enrollment of the first patient to a Phase II study testing DCVAC/OvCa in combination with ...

29 November 2017 news cancer | chemotherapy

Continue Reading →

news

Ozanimod Superior to Avonex in Treating Relapsing MS in Phase 3 Trials, Celgene Reports

Celgene released the results of two Phase 3 trials showing that patients with relapsing multiple sclerosis (MS) who were treated with ozanimod had lower relapse rates...

22 November 2017 news autoimmune | FDA

Continue Reading →

news

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-d...

22 November 2017 news biopharmaceutical | clinical research

Continue Reading →

news

New study results support use of DiviTum ® for evaluation of pancreatic cancer

In collaboration with University of Heidelberg, Germany, results from a clinical study of pancreatic cancer are published in the Pancreas scientific journal. The res...

22 November 2017 news cancer | clinical

Continue Reading →

news

Arcus Biosciences secures funding to advance clinical programs for AB928

Clinical-stage biotechnology company Arcus Biosciences has completed a $107m series C financing, bringing the total equity capital to around $227m. The proceeds from ...

22 November 2017 news biotechnology | cancer

Continue Reading →

news

Summit completes initial dosing trials on Duchenne muscular dystrophy drug

Summit Therapeutics has completed the half-way stage of dosing of its Duchenne Muscular Dystrophy (DMD) candidate ezutromid in a 48-week phase 2 trial, dubbed PhaseOu...

22 November 2017 news approval | Duchenne

Continue Reading →